United States: 美国安进公司新起诉以寻求关于美国生物性产品价格竞争与创新法案


In the most recent lawsuit involving the Biologics Price Competition and Innovation Act ("BPCIA"), Amgen filed a complaint on March 4, 2016, seeking a declaration that Sandoz has failed to participate in the BPCIA's information-exchange provisions and an order compelling Sandoz to do so. Notably, the complaint does not include a claim for patent infringement based on Sandoz's application for FDA approval to market a biosimilar version of the drug product Neulasta?. Rather, the complaint is self-described as "an action to enforce the patent-dispute-resolution provisions of the BPCIA." This is a departure from Amgen's February 26, 2016 complaint against Sandoz (concerning the immunosuppressant Enbrel?), in which Amgen alleged similar behavior by Sandoz but brought only claims for patent infringement.

The BPCIA established a unique and elaborate process for information exchange between the biosimilar applicant and the reference product sponsor ("RPS") to resolve patent disputes. The Federal Circuit summarized the process, which has become known as the "patent dance," as follows:

Under that process, codified at 42 U.S.C. § 262(l), the biosimilar applicant grants the RPS confidential access to its aBLA [abbreviated Biologics License Application] and the manufacturing information regarding the biosimilar product no later than 20 days after the FDA accepts its application for review. Id. § 262(l)(1)-(2). The parties then exchange lists of patents for which they believe a claim of patent infringement could reasonably be asserted by the RPS, as well as their respective positions on infringement, validity, and enforceability of those patents. Id. § 262(l)(3). Following that exchange, which could take up to six months, the parties negotiate to formulate a list of patents ("listed patents") that would be the subject of an immediate infringement action, id. § 262(l)(4)-(5), and the RPS then sues the biosimilar applicant within 30 days, id. § 262(l)(6). That information exchange and negotiation thus contemplates an immediate infringement action brought by the RPS based only on listed patents.

Amgen Inc. v. Sandoz Inc.. In Amgen, the Federal Circuit held that a biosimilar applicant (Sandoz in that case as well) did not violate the BPCIA by failing to disclose its application and manufacturing information as set forth in § 262(l)(1)-(2).

The newly filed Amgen complaint raises two related but separate issues: (i) whether a biosimilar applicant must participate in the patent selection procedures set forth in § 262(l)(4)-(5) after providing the RPS with its application and manufacturing information, as well as its contentions as to invalidity, unenforceability, and noninfringement, and (ii) whether an applicant's decision not to participate compels the RPS to file a patent infringement lawsuit under § 262(l)(6) prior to the negotiation and exchange of patent lists as set forth under § 262(l)(4) and, if necessary, § 262(l)(5).

Specifically, Amgen has alleged that Sandoz filed an aBLA with the FDA "in order to obtain approval to commercially manufacture, use, offer to sell, and sell, and import into the United States the Sandoz Pegfilgrastim Product, a biosimilar version of Plaintiffs' NEULASTA? (pegfilgrastim) product." According to Amgen, "NEULASTA? is indicated to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs."

As it did in its Enbrel? complaint, Amgen asserts that Sandoz engaged in the initial stages of the "patent dance" by providing Amgen access to documents Sandoz "represented to constitute its aBLA and information relating to the manufacturing process for the Sandoz Pegfilgrastim Product." In response, and pursuant to § 262(l)(3)(A), Amgen provided Sandoz with a list of two patents (U.S. Patent Nos. 8,940,878 and 5,824,784) "for which it believed a claim of patent infringement could reasonably be asserted against the Sandoz Pegfilgrastim Product." In response, Sandoz provided "contentions that the '878 and '784 patents are invalid, unenforceable, or will not be infringed by the commercial marketing of the biological product that is the subject of the Sandoz aBLA."

Sandoz, however, "also stated that it no longer wished to follow the strictures of the BPCIA because it effectively had Plaintiffs' positions pursuant to 42 U.S.C. § 262(l)(3)(C)" and that it "was 'waiving' its right to receive Plaintiffs' statement pursuant to 42 U.S.C. § 262(l)(3)(C), and declared that negotiations pursuant to 42 U.S.C. § 262(l)(4) and (5) [regarding the identity of patents that would be subject to a patent infringement suit] were unnecessary." Amgen further alleges that Sandoz "then insisted that Plaintiffs file an action for patent infringement pursuant to 42 U.S.C. § 262(l)(6) within 30 days, i.e., by March 4, 2016," and if Plaintiffs did not do so, then "the penalty for an untimely suit—that the 'sole and exclusive remedy' for any infringement be limited to a 'reasonable royalty'—applies."

Accordingly, Amgen is seeking a declaration that Sandoz is required to comply with § 262(l)(4) and (5), that Sandoz's failure to comply with those provisions "means there can be no 'immediate patent infringement action' under 42 U.S.C. § 262(l)(6)," and that Amgen's "not filing a patent infringement action by March 4, 2016" does not deprive it "of the remedies for infringement available under 35 U.S.C. § 271(e)(4), including lost profits damages and injunctive relief." Amgen did not assert an alternative claim for patent infringement.  

This case highlights yet another dispute between an RPS and a biosimilar applicant as they navigate through the uncharted waters of the BPCIA's patent dance. In attempting to forego Amgen's contentions regarding infringement, validity, and enforceability under § 262(l)(3) and the subsequent negotiation over the list of patents to be litigated, Sandoz is attempting to accelerate the time by which Amgen must file a patent infringement action by as much as 80 days or more, which is significant given reports that Neulasta? generates more than $4 billion in annual revenues.

The current district court case is pending in the Newark division in the District of New Jersey (Civil Action No. 16-cv-01276) and has been assigned to Judge Stanley R. Chesler and Magistrate Judge Cathy L. Waldor. Judge Chesler is one of the designated Patent Pilot Program judges in the District of New Jersey. Congress established the Patent Pilot Program in 2011 to "encourage enhancement of expertise" in patent cases among district judges. The program directs patent cases to specific judges who volunteer to become "pilot judges."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.